Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoSec Medical Inc ONCSQ

Healthcare Biotechnology
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec... see more

Recent & Breaking News (GREY:ONCSQ)

OncoSec Provides Leadership Update

PR Newswire August 16, 2021

OncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of "Cold" Tumors to "Hot" Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy

PR Newswire September 27, 2017

OncoSec to Present at the Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 26, 2017

OncoSec Appoints Industry Leader Daniel J. O'Connor to its Board of Directors

PR Newswire September 7, 2017

OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences

PR Newswire September 6, 2017

OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors

PR Newswire September 5, 2017

OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.

PR Newswire June 12, 2017

OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma

PR Newswire June 8, 2017

OncoSec to Present at LD Micro Invitational

PR Newswire June 2, 2017

OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017

PR Newswire June 1, 2017

OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017

PR Newswire May 11, 2017

OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma

PR Newswire May 10, 2017

OncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017

PR Newswire May 2, 2017

How These Biotech Stocks are Faring? -- ContraVir Pharma, Intra-Cellular Therapies, Nivalis Therapeutics, and OncoSec Medical

PR Newswire May 2, 2017

Heat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire April 5, 2017

OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting

PR Newswire April 3, 2017

OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017

PR Newswire March 28, 2017

OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models

PR Newswire March 21, 2017

OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017

PR Newswire March 16, 2017

OncoSec Announces First Technology Access Program Agreement with Inhibrx

PR Newswire March 14, 2017